CAS NO:68767-14-6 Loxoprofen
CAS NO:68767-14-6 NAME:Loxoprofen MF：C15H18O3 MW：246.31 EINECS：1806241-263-5 Flash point:220.7 °C Appearance:White to Off-White solid Purity:98% COA:Provide Sample:Negotiable
Categories：
Life Science Chemicals
Pharmaceutical Intermediates
Email：sale06@alfachem.cn
Product introduction
| PRODUCT NAME | Loxoprofen |
| CAS NO | 68767-14-6 |
| MP | 108.5-111° |
| BP | 417.9 °C |
| DENSITY | 1.182±0.06 g/cm3(Predicted) |
| STORAGE | Sealed in dry,Room Temperature |
| DELIVERY | 2-3DAYS |
| PACKAGE | According client's request |
Description of Loxoprofen's CAS：68767-14-6
Loxoprofen's CAS：68767-14-6 active form and its analogues have been synthesized using methods such as enzymatic kinetic resolution/racemization and stereoselective biocatalytic reduction.
Loxoprofen CAS：68767-14-6 is a high-melting polymorph of loxoprofen, which is a nonsteroidal anti-inflammatory drug. Loxoprofen is used for the relief of pain and inflammation in patients with rheumatoid arthritis and osteoarthritis. It has been shown to be useful as an intermediate in the synthesis of other compounds, such as pharmaceuticals, pesticides, and dyes. Loxoprofen has also been found to be a useful building block in organic synthesis reactions that require high quality reagents.
Applications of Loxoprofen's CAS：68767-14-6
1)Solubility Optimization
Loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID), has seen advancements in its solubility optimization.
2)Transdermal Delivery Enhancement
3)Metabolism and Drug Interaction
4)Bioactivation and Pharmacological Activity
Studies have focused on the bioactivation of Loxoprofen to its active metabolite in human skin, emphasizing the role of carbonyl reductase 1 (CBR1).
5)Controlled Release Formulations
Developments in controlled release formulations of Loxoprofen have been made using hydroxypropylmethyl cellulose (HPMC) and pectin.
6)Impact on Intestinal Barrier Function
Research has explored the impact of Loxoprofen on intestinal epithelial barrier function (EBF). Loxoprofen enhances EBF, suggesting its potential therapeutic application in conditions like inflammatory bowel disease.
7)Novel Nanosponge Formulations
Innovations in nanosponge formulations of Loxoprofen have been explored. These nanosponges, incorporated into gel formulations, offer controlled drug release and enhanced skin permeation, potentially improving bioavailability and therapeutic efficacy
Key words:
Related Products
Related Products
Inquiry
Phone/WhatsApp:
Email:
Through its excellent service and product qualities, VT Chemical has cooperated with many famous customers all over the world, eg. TCI, Covestro, etc.
HUATAO GROUP
Leave Message
SAF Coolest v1.3.1.2 设置面板 MFBSX-AJYI-DZAAE-ZAQ
无数据提示
Sorry, the current column is being updated, please look forward to it!
You can view other columns